Drug news

Hyaluronate drop starting a phase II in the US.

Seikagaku Initiates a Phase II Clinical Trial in the United States for SI-614, Indicated for Treatment of Dry Eye

Tokyo, Japan, January, 2012—Seikagaku Corporation (hereafter “Seikagaku”) (head office: Chiyoda-ku, Tokyo) hereby announces that SI-614 has entered into a Phase II clinical trial in the United States (U.S.) for the treatment of dry eye....

SI-614 is a modified hyaluronate with an excellent tear

...

Finally, some news on CF101. Purchased in November by Denali Concrete Management, and as of December started enrolling for the Phase III trial. Ambitious endpoint.

Denali Concrete Management Inc. Announces the Commencement of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study

CARSON CITY, Nev., Dec. 21, 2011 /PRNewswire/ -- Denali Concrete Management Inc. DCMG announced today that it has commenced patient enrollment for a phase 3 clinical study of the safety

...

Novozymes Biopharma announced R-Tech Ueno (Japanese company) will be using Albucult in a dry eye drug. Albucult is albumin, a component of serum (aka autologous serum eyedrops). I've posted about it once or twice in the past. It's also been listed on R-Tech Ueno's site for a long time so I'm not sure why it's news but hopefully it means it's going to get studied, which would be great.

Novozymes Biopharma supplies R-Tech Ueno with Albucult® for use in unique dry eye therapy
...

On Nov. 4th, RegeneRx Biopharma announced results of their 30-day clinical trial. The drug failed to meet either of the two primary outcome measures they were targeting; however, they did identify some sign & symptom improvements. A follow-up press report clarified their position on this and a report put out on Jan 5th indicates they will be shifting the focus of further research on the drug.

While the study did not meet the two primary outcome measures selected prior to the beginning

...

Early stage research but sounds promising.

VGX-100 Identified as Potential New Therapy for Dry Eye Disease

MELBOURNE, Australia, Sept. 13, 2011 /PRNewswire via COMTEX/ -- Data published in the scientific journal Archives of Ophthalmology generated by investigators at the Schepens Eye Research Institute led by Harvard University Professor Reza Dana.

VGX-100 significantly reduced inflammation and corneal epitheliopathy in a mouse model of Dry Eye Disease.

...